血性恶性瘤中rituximab使用的十年趋势:使用意大利VALORE分布式数据库网络进行的多区域现实研究
Federica Soardo1, Andrea Spini1, Luca L'Abbate1
1Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Expert opinion on biological therapy
|October 31, 2025
概括
意大利里图西马布的使用转向了治疗非霍奇金淋巴瘤和慢性淋巴细胞白血病的生物仿制药. 总的来说,近来瑞思西马布的患病率下降,受到大流行和新治疗方法的影响.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药物经济学 药物经济学
背景情况:
- 利图西马布是治疗非霍奇金淋巴瘤 (nHL) 和慢性淋巴细胞白血病 (CLL) 的关键疗法.
- 皮下和生物相似配方的引入改变了治疗的格局.
- 监管变化影响了瑞思西马布的市场动态.
研究的目的:
- 评估意大利nHL和CLL中rituximab使用趋势.
- 为了评估生物类似药和皮肤下药的Rituximab配方的吸收.
- 分析原始药物和生物类似药物Rituximab产品之间的转移.
主要方法:
- 使用VALORE数据库网络 (2012-2022) 的回顾性队列研究.
- 包括患有nHL或CLL的患者和至少一个Rituximab处方.
- 估计每年流行率和评估不同配方之间的转换率.
主要成果:
- 利图西马布的流行率在2019年达到峰值,到2022年下降,原始剂的使用量显著下降.
- 在nHL和CLL中,原始剂转化为生物类药物的转化率大幅增加.
- 在nHL中观察到更高的生物类似物到原始物切换率,通常与皮下配方有关.
结论:
- 在意大利,从原始药物转向生物类似药Rituximab发生了明显的转变.
- 近期利图西马布使用量的下降可能归因于COVID-19大流行和不断变化的治疗模式.
- 这项研究强调了血液恶性瘤治疗选择的动态性质.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.7K
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
54.0K
相关概念视频
Bone Marrow Sampling and Transplants
801
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
801
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Therapeutic Drug Monitoring: Affecting Factors
163
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
163
Rous Sarcoma Virus (RSV) and Cancer
6.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
6.1K
Blood Transfusion and Agglutination
13.9K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
13.9K
